Head to Head Survey: NovaBay Pharmaceuticals (NBY) and Celyad SA (CYAD)
NovaBay Pharmaceuticals (NYSE: NBY) and Celyad SA (NASDAQ:CYAD) are both small-cap biotechnology & medical research – nec companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.
This table compares NovaBay Pharmaceuticals and Celyad SA’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares NovaBay Pharmaceuticals and Celyad SA’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Celyad SA||$9.43 million||54.11||-$26.12 million||N/A||N/A|
NovaBay Pharmaceuticals has higher revenue, but lower earnings than Celyad SA.
Institutional & Insider Ownership
3.4% of Celyad SA shares are held by institutional investors. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This is a summary of current ratings and price targets for NovaBay Pharmaceuticals and Celyad SA, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NovaBay Pharmaceuticals currently has a consensus target price of $6.75, suggesting a potential upside of 57.16%. Celyad SA has a consensus target price of $74.00, suggesting a potential upside of 43.00%. Given NovaBay Pharmaceuticals’ higher possible upside, equities analysts plainly believe NovaBay Pharmaceuticals is more favorable than Celyad SA.
Risk & Volatility
NovaBay Pharmaceuticals has a beta of -0.69, meaning that its stock price is 169% less volatile than the S&P 500. Comparatively, Celyad SA has a beta of 1.6, meaning that its stock price is 60% more volatile than the S&P 500.
Celyad SA beats NovaBay Pharmaceuticals on 7 of the 9 factors compared between the two stocks.
About NovaBay Pharmaceuticals
NovaBay Pharmaceuticals, Inc., formerly NovaCal Pharmaceuticals, Inc., is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company’s dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.
About Celyad SA
Celyad SA, formerly Cardio3 Biosciences SA is a Belgium-based drug developing company. The Company develops stem cell-based therapies for cardiovascular disease. The Company focuses on developing regenerative therapies to treat illnesses where cardiac tissue is lost due to chronic or acute injury. The Company’s product, C-Cure, allows the differentiation of a patient’s own cells into cardiopoeitic cells which grow into new heart cells and repair heart muscle. C-Cure consists of autologous adult stem cells guided in vitro to the cardiac lineage before implantation in the failing heart. Furthermore, the Company is involved in the field of immuno-oncology, through its subsidiary, OnCyte.
Receive News & Ratings for NovaBay Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NovaBay Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.